Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended 9 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
REVENUE, NET        
Products $ 22,357 $ 413,109 $ 192,011 $ 472,509
Services 147,218 433,295
Total revenues, net 169,575 413,109 625,306 472,509
COST OF REVENUE        
Products 17,137 379,582 167,546 439,740
Services 34,206 81,967
Total costs of revenue 51,343 379,582 249,513 439,740
GROSS MARGIN 118,232 33,527 375,793 32,769
EXPENSES        
Sales and marketing 50,590 100,730 256,775 556,167
General and administrative 997,055 1,317,469 2,271,546 1,712,667
Depreciation and amortization 40,828 292 120,324 877
TOTAL OPERATING EXPENSES 1,088,473 1,418,491 2,648,645 2,269,711
OPERATING LOSS (970,241) (1,384,964) (2,272,852) (2,236,942)
Other Income (Expense)        
Change in fair value of equity investments (327,381) (327,381) 404,763
Change in fair value of derivative (39,231) (34,977)
Interest Expense (89,017) (506,579) (153,818) (574,880)
Total other (expense), net (455,629) (506,579) (516,176) (170,117)
NET LOSS (1,425,870) (1,891,543) (2,789,028) (2,407,059)
Less: Net income (loss) attributable to non controlling interest 72,480 (234) 233,995 9,358
NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP. $ (1,353,390) $ (1,891,777) $ (2,555,033) $ (2,397,701)
LOSS PER COMMON SHARE $ (0.10) $ (0.16) $ (0.19) $ (0.22)
WEIGHTED AVERAGE SHARES OUTSTANDING        
Basic and diluted 13,649,254 11,797,297 13,555,111 11,150,168